Navigation Links
Phase III data show efficacy/safety of iclaprim in patients with complicated skin infections
Date:10/27/2008

patients. In a combined efficacy analysis, the clinical cure rate at the test-of-cure visit was 82.2 percent for iclaprim versus 85.3 percent for linezolid in the intent-to-treat population and cure rates were 92.3 percent and 97.8 percent, respectively, in the per protocol population. Data from the studies also show that iclaprim exhibited a high eradication rate for MRSA (76.4 percent), which was comparable to that of linezolid (78.7 percent).

Overall, iclaprim was found to be safe and well-tolerated at a dose of 0.8 mg/kg in the Phase III ASSIST trials. Adverse events were found to be less frequent among patients treated with iclaprim as compared to linezolid. In earlier Phase I trials, iclaprim was shown to have a low propensity for interactions with other drugs.

"These data further support the safety and efficacy of iclaprim as a potential treatment against complicated skin and skin structure infections," said Jrgen Raths MD, President and CEO of Arpida. "Arpida remains encouraged and optimistic about the potential of iclaprim for the treatment of MRSA and related infections, and looks forward to bringing iclaprim to market, providing a new treatment option for physicians."

The ASSIST Trials

The ASSIST trials were randomized, multi-center, double-blind, Phase III studies designed to establish the efficacy and safety of iclaprim in the treatment of patients with cSSSI known or suspected to be caused by Gram-positive pathogens. The trials were of essentially identical design, making a combined analysis of iclaprim possible in a larger population. A 95 percent confidence interval was used to determine statistical significance of study data and the pre-specified non-inferiority margin (-12.5 percent) was met in all populations in both trials.

A total of 991 patients, 18 years old and over with cSSSIs were enrolled in the trials. Patients were treated for 10 to 14 days with either 0.8 mg/kg iclaprim or 600 mg linezol
'/>"/>

Contact: Dr. Jrgen Raths
41-614-179-660
Zeno Group
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet
2. Improved foam for varicose veins found to be safe in preliminary results from phase II trial
3. Moms obesity during conception phase may set the stage for offsprings obesity risk
4. Liquid crystal phases of tiny DNA molecules point up new scenario for first life on Earth
5. HGS announces positive Phase 2 LymphoStat-B at ACR meeting
6. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
7. CABI helps phase out dangerous pesticide in EU
8. SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma
9. New test promises quicker, more accurate evaluation for cystic fibrosis patients
10. How eating fruit and vegetables can improve cancer patients response to chemotherapy
11. UCSF Fresno leading-edge study lends hope to emphysema patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... adipocytes, or fat cells, are inherently different. Each of ... its own role in metabolism. In the human body, ... Its primary function is energy storage. On the other ... but are only found in a few places in ... special type of brown adipocytes, appear mixed with brown ...
(Date:7/31/2014)... studies have shown that marine noise can affect animal ... the Universities of Bristol and Exeter and the cole ... demonstrated that boat noise stops embryonic development and increases ... the sea slug Stylocheilus striatus used in ... away and later feed on toxic alga but this ...
(Date:7/30/2014)... epigenetic processes to regulate its genes, and adapt to ... of the genome regulation taking place in the truffle, ... Biology and illustrates how the truffle deals with ... authors say this may shed light on how traits ... (Tuber melanosporum), also known as Prigord truffles, have a ...
Breaking Biology News(10 mins):Hope for the overweight 2Boat noise impacts development and survival of sea hares 2How black truffles deal with the jumpers in their genome 2
... Fast development is often perceived as an advantage, ... readiness to cope with the challenges that it poses. ... and University of California, Santa Cruz, and published in ... the acceleration of developmental rate incurs potentially lethal physiological ...
... molding some snow into a ball and hurling it or ... can? New research from Indiana University and the University of ... readily learn to throw long distances. This research also suggests ... in a way critical to our very existence. ...
... N.C. Despite what you might have heard, genetic sequencing ... Duke University Medical Center have shown that functional tests are ... of sequencing studies as they relate to disease, using a ... patients to have many different traits. "Right now ...
Cached Biology News:Faster development might have its costs 2Faster development might have its costs 3IU study: Humans' critical ability to throw long distances aided by an illusion 2IU study: Humans' critical ability to throw long distances aided by an illusion 3Genetic sequencing alone doesn't offer a true picture of human disease 2Genetic sequencing alone doesn't offer a true picture of human disease 3
(Date:7/31/2014)... BLOOMINGTON, Ind. -- Chemists at Indiana University Bloomington ... in bricks-and-mortar fashion, a development with potential value ... as field-effect transistors and photovoltaic cells. , Their ... 3D Crystalline Solids and 2D Self-Assembled Crystals," has ... a journal of the Royal Society of Chemistry. ...
(Date:7/31/2014)... Graphite Metallizing Corporation announces GRAPHALLOY® bearings ... are uniquely suited to prevent loss of lubrication that ... high temperatures . , Recently, a manufacturer of ... at Graphite Metallizing to overcome problems with movement of ... pans containing blocks of powder mixture are loaded onto ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 CollabRx, Inc. ... inform therapeutic decision-making in oncology, today announced that it ... 2014 to discuss the Company's financial results for the ... update about the business in the current fiscal year. ... beginning on Thursday, August 14, 2014, at 5 p.m. ...
(Date:7/31/2014)... Francisco, Calif. (PRWEB) July 31, 2014 ... newly diagnosed patients with an overview of the disease ... management of drug side effects, as well as updates ... “We’re grateful to Dr. Sandy Srinivas for organizing this ... survivor of kidney cancer. “Sandy and her colleagues have ...
Breaking Biology Technology:Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 3Graphite Metallizing Announces Bearings for High Temperature Oven Applications 2Graphite Metallizing Announces Bearings for High Temperature Oven Applications 3CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2
... deCODE genetics,(Nasdaq: DCGN ) today announced its ... 2008. A conference call to discuss the,quarter,s results, ... webcast live tomorrow, Friday, November 7, at 8:00am ... third quarter 2008 was $11.3 million, compared,to $22.2 ...
... NGX-4010 for management of pain associated ... with PHN, ... review for NGX-4010 ... NGSX ), a biopharmaceutical company focused on developing and,commercializing novel pain management ...
... While Public Relations has,long been used as a ... ability to reach consumers has never been greater. ... the traditional press,release as effective and low-cost methods ... was conducted by Best Practices, LLC to,identify what ...
Cached Biology Technology:deCODE genetics Announces Third Quarter 2008 Financial Results 2deCODE genetics Announces Third Quarter 2008 Financial Results 3deCODE genetics Announces Third Quarter 2008 Financial Results 4deCODE genetics Announces Third Quarter 2008 Financial Results 5deCODE genetics Announces Third Quarter 2008 Financial Results 6deCODE genetics Announces Third Quarter 2008 Financial Results 7deCODE genetics Announces Third Quarter 2008 Financial Results 8deCODE genetics Announces Third Quarter 2008 Financial Results 9deCODE genetics Announces Third Quarter 2008 Financial Results 10deCODE genetics Announces Third Quarter 2008 Financial Results 11deCODE genetics Announces Third Quarter 2008 Financial Results 12NeurogesX Reports Third Quarter 2008 Results 2NeurogesX Reports Third Quarter 2008 Results 3NeurogesX Reports Third Quarter 2008 Results 4NeurogesX Reports Third Quarter 2008 Results 5NeurogesX Reports Third Quarter 2008 Results 6NeurogesX Reports Third Quarter 2008 Results 7NeurogesX Reports Third Quarter 2008 Results 8NeurogesX Reports Third Quarter 2008 Results 9New Study Shares Best Practices in Biopharma Public Relations 2
Angiotensin Converting Enzyme [Porcine Kidney, ACE, Peptidyl-dipeptidase A]...
Oven mesh sheets, large, 23 x 23cm, pack of 5...
Preparation Note: Prepared essentially by method of Singer, T.P., J. Biol. Chem., 174, 11 (1948). Quality Clarifier: Contains lipase Unit Definition: One unit will hydrolyze 1.0 μmole of p-ni...
... Analysis Note: Protein determined by Biuret ... 25 mM Tris-HCl, pH 7.6, 1 mM ... 2 Preparation Unit Definition: One unit ... per minute at pH 9.8 at 37 ...
Biology Products: